1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.

Slides:

Advertisements

Similar presentations

Breast cancer chemoprevention in the high-risk patient

Advertisements

Study of Tamoxifen and Raloxifene (STAR): Initial Findings from the NSABP P-2 Breast Cancer Prevention Study D.L. Wickerham, J.P. Costantino, V. Vogel,

Breast Cancer Risk and Risk Assessment Models

Why can’t we prevent breast cancer? Actually, we can … The treatment can be worse than the disease – The preventative can be worse than the risk Topics.

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

Every Woman, Every Time: Disparities in Breast Cancer Tony L. Weaver, D.O. ALOMA 2015.

Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)

Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy The Women’s Health Initiative Randomized Controlled Trial JAMA 2004;291:

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

1 SERM’s IES Winter Conference Iris Vered, Sheba Medical Center Tel Hashomer.

Christina Laukaitis, MD, PhD, FACP 22 June * To continue to increase the competitive stance of cancer research and training at Northern Arizona.

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.

Menopause: The Journal of The North American Menopause Society

The P-4 NSABP Trial: NCAB Subcommittee Recommendations Bruce A. Chabner, MD June 16, 2007.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Jump to first page First pregnancy after age 30 (RR 1.48). BMI >29 (RR 1.48). Being a college graduate, independent of OB-GYN history (RR 1.36). (Collaborative.

Cancer Estimated US Cancer Cases Cancer Incidence Rates for Women, USA.

Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.

Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

The Women’s Health Initiative Hormone Trials The Estrogen Only (women with a hysterectomy at baseline) and the Estrogen + Progestin (women with a uterus)

Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.

FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

MacLennan Selected Risks and Benefits after 5 Years of combined estrogen and progestogen HRT for all women aged (WHI Study, 2002) OESTROGEN WITH.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

By: Erin Hutzell. Background: Breast Cancer Second leading cause of death due to cancer among women in in 3 women diagnosed with cancer is diagnosed.

1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.

DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015

Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.

MENAPOUSE. Natural Surgical premature RETROSPECTIVE Cessation of menstruation for 12 months In the absence of other physiological or psychological.

Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.

STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive

Anastrozole (‘Arimidex’): a new standard of care?

4S: Scandinavian Simvastatin Survival Study

‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.

SNDA Letrozole (Femara®) Indication: First-line therapy in postmenopausal women with advanced breast cancer. Prior approval: Second-line therapy.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.

A RAY OF HOPE: TAMOXIFEN POWERPOINT PRESENTATION BY NEIL RAKHOLIA

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

Chemoprevention of cancer Dr Manal Kahwaji Cancer fighting day Feb 2, 2016.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Practical Issues in Counseling Healthy Women About.

Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,

Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Date of download: 6/27/2016 From: Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer Ann Intern Med.

Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

M.D. Browning, M.D. ‘77.  Most Common Cancer of Female Reproductive System  60,000/year with 10,000 deaths  Normal Cells in the Endometrium.

Breast Cancer Updates Risks, Genetics, DCIS

JOURNAL OF CLINICAL ONCOLOGY 25:

First time a CETP inhibitor shows reduction of serious CV events

Breast Health Katherine B. Lee, MD, FACP April 26, 2018.

Volume 381, Issue 9880, Pages (May 2013)

Presentation transcript:

1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer

2 # Events Placebo93 Tamoxifen # Events Placebo250 Tamoxifen Cumulative Rate/1000 Invasive Breast Cancer Noninvasive Breast Cancer Time to Breast Cancer (Years) P < P= NSABP P1 Study

3 STRATIFICATION Age Gail Model Risk Race History of LCIS Hysterectomy Tamoxifen 20 mg/day x 5 years Study Design STAR Raloxifene 60 mg/day x 5 years Risk-Eligible Postmenopausal Women

4 Inclusion and Exclusion Criteria STAR Inclusion –At least 35 years of age –Postmenopausal –Risk eligible Lobular carcinoma in situ or 5-year Gail risk of breast cancer >1.66% Exclusion History of: –Invasive breast cancer –Ductal carcinoma in situ –DVT, PE –CVA, TIA –Uncontrolled diabetes, hypertension or atrial fibrillation

5 Primary Aims STAR The primary aim of the study was to determine which of the following three statements is true: –Compared to tamoxifen, raloxifene significantly reduces the incidence rate of IBC –Compared to raloxifene, tamoxifen significantly reduces the incidence rate of IBC –The statistical superiority of one of the treatments cannot be demonstrated and the choice of therapy should be based on benefit/risk considerations

6 Primary Objective STAR Evaluate the effect of raloxifene versus tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk.

7 Secondary Objectives STAR Non-invasive breast cancer Endometrial cancer Ischemic heart disease Fractures of the hip, spine or wrist Toxicity and side effects

8 Screening, Accrual and Follow-up STAR Screened184,460 Eligible96,368 Randomized19,747 Woman-years of follow-up79,173 Average follow-up (years) 4.06

9 Baseline Characteristics STAR Age (mean)58.5 Caucasian93% Hysterectomy51% First degree relative(s) with breast cancer71% History of Lobular carcinoma in situ9% Atypical hyperplasia23% 5-year predicted Gail risk of invasive breast cancer (mean)4.03%

10 Effects on Invasive Breast Cancer STAR RR (95% CI) = 1.02 (0.82, 1.27)

11 Invasive Breast Cancer STAR

12 Invasive Breast Cancer by 5-year Predicted Risk STAR

13 Invasive Breast Cancer Tumor Characteristics STAR Tamoxifen n=168 Raloxifene n=173 Estrogen Receptor Status +72%69% -28%31% Tumor Size <129%39% %54% >3.110%8% Nodal Status -74%80% +26%20%

Invasive Breast Cancer in Women with a History of LCIS or Atypical Hyperplasia STAR

15 Non-Invasive Breast Cancer STAR

16 Non-Invasive Breast Cancer STAR Tamoxifen (n) Raloxifene (n) RR (95%CI) DCIS ( ) LCIS ( ) Mixed ( )

17 Uterine Cancer STAR

18 Tamoxifen (n) Raloxifene (n) RR (95% CI) Hysterectomy during study (0.28, 0.47) Hyperplasia (0.09, 0.28) with atypia (0.01, 0.56) w/o atypia (0.09, 0.30) Uterine Hyperplasia and Hysterectomy STAR

19 Ischemic Heart Disease STAR Tamoxifen (n) Raloxifene (n) RR (95% CI) Myocardial infarction ( ) Severe angina ( ) Acute ischemic syndrome ( ) Total ( )

20 Osteoporotic Fractures STAR Tamoxifen (n) Raloxifene (n) RR (95% CI) Hip ( ) Spine ( ) Wrist ( ) Total* ( ) *Columns not additive because one patient may have had fractures at multiple sites.

21 Mortality STAR Tamoxifen (n) Raloxifene (n) Cancer52 Breast cancer52 Circulatory/vascular2521 Other3231 Any cause RR (95% CI) 0.95 ( )

22 Venous Thromboembolic Events STAR

23 Cataracts and Cataract Surgery During Follow-up STAR RR = 0.78 (95% CI = 0.68–0.91) RR = 0.81 (95% CI = 0.68–0.96)

24 Summary STAR Compared with tamoxifen, raloxifene was: similar in decreasing the risk of invasive breast cancer not as effective at decreasing the risk of non-invasive breast cancer associated with fewer: –adverse events related to uterus –VTEs –cataracts and cataract surgery